Companies | Deal | Date Announced |
Alnylam Pharmaceuticals and Merck | Alnylam is developing siRNAs against a number of Merck targets. Under the deal, Merck may develop the drug candidates alone or in partnership with Alnylam. |
Sept.
9, 2003 -
RNAi News, 9/12/2003 |
Sirna Therapeutics and Eli Lilly | Sirna generated modified siRNAs against Lilly-selected oncology targets. Lilly had the option of licensing promising candidates under the now-ended deal. |
Jan.
27, 2004 -
RNAi News, 1/30/2004 |
Alnylam Pharmaceuticals and Merck | The companies partnered on the development of RNAi-based drugs for ocular diseases. This arrangement was later dropped and the companies' alliances were consolidated. |
June
30, 2004 -
RNAi News, 7/2/2004 |
Alnylam Pharmaceuticals and Medtronic | Alnylam is developing RNAi-based drugs for various diseases, which will be delivered using Medtronic devices to specific locations in the nervous system. |
Feb.
9, 2005 -
RNAi News, 2/11/2005 |
Alnylam Pharmaceuticals and Novartis | The companies are collaborating on developing RNAi drugs against Novartis-selected targets in multiple disease areas. As part of the deal, Novartis paid Alnylam an upfront fee and bought a 19.9-percent stake in the RNAi firm. |
Sept.
7, 2005 -
RNAi News, 9/9/2005 |
Sirna Therapeutics and GlaxoSmithKline | Sirna is developing optimized and formulated siRNAs against targets specified by the GlaxoSmithKline, which will handle all development and commercialization activities for the drugs. In exchange, Sirna received $12 million upfront and stands to receive up to $700 million in milestones and royalties. |
April
3, 2006 -
RNAi News, 4/6/2006 |
Sirna Therapeutics and Allergan | Allergan acquired the rights to Sirna's phase I age-related macular degeneration drug Sirna-027 for $5 million upfront, up to $245 million in milestones, and royalties. |
Sept.
29, 2005 -
RNAi News, 10/7/2005 |
Dharmacon and Alcon | Dharmacon is developing siRNAs against ocular disease gene targets, with Alcon selecting the most promising candidates for development. |
Oct.
19, 2005 -
RNAi News, 10/21/2005 |
Dharmacon and Abbott | The companies are working together to discover siRNA-based therapeutics in multiple indications including cancer. |
July
6, 2006 -
RNAi News, 7/6/2006 |
Alnylam Pharmaceuticals and Biogen Idec | Alnylam is helping Biogen Idec develop an RNAi-based treatment for progressive multifocal leukoencephalopathy, an opportunistic viral infection of the brain that has been associated with Biogen Idec's multiple sclerosis drug Tysabri. |
Sept.
20, 2006 -
RNAi News, 9/21/2006 |
Quark Biotech and Pfizer | Pfizer acquired from Quark RTP-801i, an siRNA-based molecule that silences the age-related macular degeneration target RTP-801. | Sept. 26,
2006 - RNAi News, 9/28/2006 |
Sirna Therapeutics and Merck | Merck agreed to buy Sirna for $1.1 billion in cash, or $13 per share. The acquisition is expected to close in the first quarter of 2007. |
Oct.
30, 2006 -
RNAi News, 11/2/2006 |